BR112022009153A2 - Compostos inibidores de óxido de nitrogênio pde-5 e/ou pde-6 - Google Patents
Compostos inibidores de óxido de nitrogênio pde-5 e/ou pde-6Info
- Publication number
- BR112022009153A2 BR112022009153A2 BR112022009153A BR112022009153A BR112022009153A2 BR 112022009153 A2 BR112022009153 A2 BR 112022009153A2 BR 112022009153 A BR112022009153 A BR 112022009153A BR 112022009153 A BR112022009153 A BR 112022009153A BR 112022009153 A2 BR112022009153 A2 BR 112022009153A2
- Authority
- BR
- Brazil
- Prior art keywords
- pde
- compounds
- nitrogen oxide
- inhibitor compounds
- compositions
- Prior art date
Links
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title abstract 11
- 150000001875 compounds Chemical class 0.000 title abstract 11
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 101100296726 Caenorhabditis elegans pde-5 gene Proteins 0.000 title 1
- 101100351285 Caenorhabditis elegans pde-6 gene Proteins 0.000 title 1
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 6
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 6
- 102000010989 Type 6 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 6
- 108010037638 Type 6 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 6
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 abstract 4
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 2
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitrogen oxide(NO) Natural products O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 abstract 2
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 208000002780 macular degeneration Diseases 0.000 abstract 2
- 208000002177 Cataract Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 108010078321 Guanylate Cyclase Proteins 0.000 abstract 1
- 102000014469 Guanylate cyclase Human genes 0.000 abstract 1
- 206010046851 Uveitis Diseases 0.000 abstract 1
- KHBQMWCZKVMBLN-IDEBNGHGSA-N benzenesulfonamide Chemical group NS(=O)(=O)[13C]1=[13CH][13CH]=[13CH][13CH]=[13CH]1 KHBQMWCZKVMBLN-IDEBNGHGSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 208000005494 xerophthalmia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
COMPOSTOS INIBIDORES DE ÓXIDO DE NITROGÊNIO PDE-5 E/OU PDE-6. A presente descrição fornece compostos inibidores de fosfodiesterase 5 (PDE-5) e/ou fosfodiesterase 6 (PDE-6) e composições incluindo os referidos compostos. Em algumas modalidades, os referidos compostos são compostos inibidores de PDE-5 e/ou -6 doadores de óxido de nitrogênio (NO) que incluem um substituinte doador contendo óxido de nitrogênio ligado a um grupo benzenossulfonamida. Os compostos podem fornecer funcionalidade dupla para aumentar a atividade da proteína quinase G (PKG) inibindo PDE-5 e PDE-6 e/ou estimulando a guanilato ciclase (sGC) através da doação de óxido de nitrogênio (NO) do substituinte doador do composto. A presente descrição também fornece métodos de uso dos referidos compostos e composições para inibir PDE-5 e/ou -6 e aumentar a atividade da proteína quinase G (PKG). Os compostos e composições encontram uso em aplicações terapêuticas, incluindo no tratamento de uma variedade de doenças oculares. Por exemplo, os compostos em questão podem ser usados como um agente terapêutico para glaucoma, degeneração macular relacionada à idade (AMD), retinopatia diabética (DR), xeroftalmia, catarata ou uveíte.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190143747A KR20210056827A (ko) | 2019-11-11 | 2019-11-11 | 신규한 벤젠설폰아미드 유도체 및 그의 용도 |
| PCT/IB2020/000950 WO2021094830A2 (en) | 2019-11-11 | 2020-11-09 | Nitrogen oxide-donating pde-5 and/or pde-6 inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022009153A2 true BR112022009153A2 (pt) | 2022-07-26 |
Family
ID=75911872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022009153A BR112022009153A2 (pt) | 2019-11-11 | 2020-11-09 | Compostos inibidores de óxido de nitrogênio pde-5 e/ou pde-6 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220380376A1 (pt) |
| EP (1) | EP4058457A4 (pt) |
| JP (1) | JP2023500947A (pt) |
| KR (2) | KR20210056827A (pt) |
| CN (1) | CN115038704A (pt) |
| AU (1) | AU2020382131A1 (pt) |
| BR (1) | BR112022009153A2 (pt) |
| CA (1) | CA3161134A1 (pt) |
| CO (1) | CO2022008136A2 (pt) |
| IL (1) | IL292900A (pt) |
| MX (1) | MX2022005639A (pt) |
| TW (1) | TW202132302A (pt) |
| WO (1) | WO2021094830A2 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022096930A2 (en) * | 2020-11-09 | 2022-05-12 | Ildong Pharmaceutical Co., Ltd. | Nitrogen oxide-donating pde-5 and/or pde-6 inhibitor compounds, and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6225315B1 (en) * | 1998-11-30 | 2001-05-01 | Pfizer Inc | Method of treating nitrate-induced tolerance |
| US6407259B1 (en) * | 2000-07-28 | 2002-06-18 | Pfizer Inc. | Process for the preparation of pyrazoles |
| EP1336602A1 (en) * | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
| US20020168424A1 (en) * | 2002-07-31 | 2002-11-14 | Dr. Mohsen Shahinpoor | Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for glaucoma |
| EP1460077B1 (en) * | 2003-03-18 | 2007-08-01 | The Jordanian Pharmaceutical Manufacturing Co. Ltd. | Novel pyrazolopyrimidones and their use as PDE inhibitors |
| US9061030B2 (en) * | 2010-11-09 | 2015-06-23 | Ironwood Pharmaceuticals, Inc. | sGC stimulators |
| US8871781B2 (en) * | 2011-11-30 | 2014-10-28 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating a subject for a lymphatic malformation |
| CN103374002B (zh) * | 2012-04-19 | 2015-07-15 | 山东轩竹医药科技有限公司 | 磷酸二酯酶-5抑制剂 |
| WO2015095515A1 (en) * | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
| WO2015175704A1 (en) * | 2014-05-14 | 2015-11-19 | The Regents Of The University Of California | Inhibitors of bacterial dna gyrase with efficacy against gram-negative bacteria |
| JP6867417B2 (ja) * | 2016-06-21 | 2021-04-28 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤としてのｎ−（置換フェニル）−スルホンアミド誘導体 |
-
2019
- 2019-11-11 KR KR1020190143747A patent/KR20210056827A/ko unknown
-
2020
- 2020-11-09 TW TW109139024A patent/TW202132302A/zh unknown
- 2020-11-09 CA CA3161134A patent/CA3161134A1/en active Pending
- 2020-11-09 KR KR1020227019828A patent/KR20220101666A/ko unknown
- 2020-11-09 MX MX2022005639A patent/MX2022005639A/es unknown
- 2020-11-09 CN CN202080092783.4A patent/CN115038704A/zh active Pending
- 2020-11-09 AU AU2020382131A patent/AU2020382131A1/en active Pending
- 2020-11-09 EP EP20886376.1A patent/EP4058457A4/en active Pending
- 2020-11-09 JP JP2022526698A patent/JP2023500947A/ja active Pending
- 2020-11-09 IL IL292900A patent/IL292900A/en unknown
- 2020-11-09 BR BR112022009153A patent/BR112022009153A2/pt not_active Application Discontinuation
- 2020-11-09 WO PCT/IB2020/000950 patent/WO2021094830A2/en unknown
-
2022
- 2022-05-10 US US17/741,327 patent/US20220380376A1/en not_active Abandoned
- 2022-06-08 CO CONC2022/0008136A patent/CO2022008136A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220380376A1 (en) | 2022-12-01 |
| AU2020382131A1 (en) | 2022-06-23 |
| IL292900A (en) | 2022-07-01 |
| CO2022008136A2 (es) | 2022-09-20 |
| KR20220101666A (ko) | 2022-07-19 |
| EP4058457A2 (en) | 2022-09-21 |
| CA3161134A1 (en) | 2021-05-20 |
| KR20210056827A (ko) | 2021-05-20 |
| TW202132302A (zh) | 2021-09-01 |
| WO2021094830A3 (en) | 2021-06-24 |
| MX2022005639A (es) | 2022-09-07 |
| WO2021094830A2 (en) | 2021-05-20 |
| CN115038704A (zh) | 2022-09-09 |
| EP4058457A4 (en) | 2023-10-18 |
| JP2023500947A (ja) | 2023-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019008458A2 (pt) | 1,2,4-triazolonas 2,4,5-trisubstituídas. | |
| MX2019010354A (es) | Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo. | |
| WO2018045276A8 (en) | Fused bicyclic sgc stimulators | |
| WO2018155916A3 (ko) | 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| BR112015016793A2 (pt) | compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim | |
| BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
| BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
| BR112012030177A2 (pt) | composto, uso do mesmo, e, composição farmacêutica | |
| GB2540638A8 (en) | Compositions, Formulations and methods for treating ocular diseases | |
| CR20210201A (es) | Nuevos compuestos antihelmínticos | |
| BR112019006047A2 (pt) | compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica | |
| BR112015024678A2 (pt) | inibidor da cinase | |
| BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
| WO2008106692B1 (en) | Pim kinase inhibitors and methods of their use | |
| MX2016009063A (es) | Preparacion farmaceutica que contiene compuesto de acido piridilaminoacetico. | |
| JOP20220131A1 (ar) | مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة | |
| BR112015019039A8 (pt) | compostos antagonistas de integrina fluorados, composição farmacêutica compreendendo ditos compostos e uso destes para tratar ou prevenir uma doença ou condição mediada por uma av integrina | |
| BR112022019057A2 (pt) | Aminotiazóis substituídos como inibidores de dgkzeta para ativação imune | |
| BR112019000293A2 (pt) | formas sólidas de um estimulador de sgc | |
| BR112015022650A2 (pt) | inibidores de cinase induzível por sal macrocíclico | |
| EA201991147A1 (ru) | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC | |
| BR112021024325A2 (pt) | Análogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida | |
| BR112022001567A2 (pt) | Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias. | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| BR112021020297A2 (pt) | Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |